Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2026)

Catalyst Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 16.64% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 16.64% YoY), and the FY2025 full-year result was $2.4 million, down 15.65% from the prior year.
• Operating Leases for Q1 2026 stood at $2.2 million, down from $2.4 million in the prior quarter.
• The five-year high for Operating Leases was $4.1 million in Q1 2022, with the low at $2.2 million in Q1 2026.
• Historically, Operating Leases has averaged $3.1 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases changed 0.0% — and 2023, when it decreased 17.39%.
• Catalyst Pharmaceuticals' Operating Leases stood at $3.6 million in 2022, then retreated by 10.37% to $3.2 million in 2023, then slipped by 12.61% to $2.8 million in 2024, then dropped by 15.65% to $2.4 million in 2025, then slipped by 4.89% to $2.2 million in 2026.
• The last three Operating Leases figures came in at $2.2 million (Q1 2026), $2.4 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.